Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT

AAPS Journal

Volumn 13, Issue 2, 2011, Pages 201-211

  Bulitta, Jurgen Bernd ^a,b   Bingölbali, Ayhan ^a   Shin, Beom Soo ^c   Landersdorfer, Cornelia Barbara ^a,b  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Catholic University of Daegu   (South Korea)

Author keywords

automated pre processing; mechanistic population pharmacokinetic pharmacodynamic modeling; nonlinear mixed effects modeling; post processing and plotting; SADAPT TRAN translator tool; scriptable ADAPT S ADAPT

Indexed keywords

ALGORITHM; ANALYTICAL ERROR; ARTICLE; AUTOMATION; COMPUTER PROGRAM; MONTE CARLO METHOD; NONLINEAR SYSTEM; POPULATION MODEL; PROCESS DEVELOPMENT; STATISTICAL MODEL;

ALGORITHMS; COMPUTER SIMULATION; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NONLINEAR DYNAMICS; PHARMACOKINETICS;

EID: 79956327970     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9257-x     Document Type: Article

References (27)

1. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ. NONMEM user's guides (1989-2009). Ellicott City: Icon Development Solutions; 2009.
2. Lavielle M. Monolix (Version 3.1)-A free software for the analysis of nonlinear mixed effects models. The Monolix Group. Paris; 2009.
3. DJ Lunn N Best A Thomas J Wakefield D Spiegelhalter 2002 Bayesian analysis of population PK/PD models: general concepts and software J Pharmacokinet Pharmacodyn 29 271 307 12449499 10.1023/A:1020206907668 1:CAS:528:DC%2BD38XntFGrt7w%3D (Pubitemid 35333143)
4. Lunn DJ, Wakefield J, Thomas A, Best N, Spiegelhalter D. PKBugs user guide. London: Imperial College School of Medicine; 1999.
5. EN Jonsson MO Karlsson 1999 Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput Methods Programs Biomed 58 51 64 10195646 10.1016/S0169-2607(98)00067-4 1:STN:280:DyaK1M3htVShsw%3D%3D (Pubitemid 29049052)
6. L Lindbom J Ribbing EN Jonsson 2004 Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming Comput Methods Programs Biomed 75 85 94 15212851 10.1016/j.cmpb.2003.11.003 (Pubitemid 38798039)
7. A Bustad D Terziivanov R Leary R Port A Schumitzky R Jelliffe 2006 Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies Clin Pharmacokinet 45 365 83 16584284 10.2165/00003088-200645040-00003
8. RW Jelliffe A Schumitzky D Bayard M Milman M Van Guilder X Wang, et al. 1998 Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals Clin Pharmacokinet 34 57 77 9474473 10.2165/00003088-199834010-00003 1:STN:280:DyaK1c7jsVyitg%3D%3D (Pubitemid 28041092)
9. Bauer RJ. S-ADAPT/MCPEM User's Guide (Version 1.56). Software for pharmacokinetic, pharmacodynamic and population data analysis. Berkeley, CA; 2008.
10. JC Earp DC Dubois DS Molano NA Pyszczynski CE Keller RR Almon, et al. 2008 Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats J Pharmacol Exp Ther 326 532 45 18448865 10.1124/jpet.108.137372 1:CAS:528:DC%2BD1cXpsVWqs7w%3D
11. CB Landersdorfer DC DuBois RR Almon WJ Jusko 2009 Mechanism-based modeling of nutritional and leptin influences on growth in normal and type 2 diabetic rats J Pharmacol Exp Ther 328 644 51 18971370 10.1124/jpet.108.144766 1:CAS:528:DC%2BD1MXhs1Kgs78%3D
12. S Ait-Oudhia JM Scherrmann W Krzyzanski 2010 Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats J Pharmacol Exp Ther 334 897 910 20501635 10.1124/jpet.110.167304 1:CAS:528:DC%2BC3cXhtFyksLzJ
13. JB Bulitta JC Yang L Yohonn NS Ly SV Brown RE D'Hondt, et al. 2010 Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model Antimicrob Agents Chemother 54 2051 62 20211900 10.1128/AAC.00881-09 1:CAS:528:DC%2BC3cXmtFelsLc%3D
14. DE Mager WJ Jusko 2008 Development of translational pharmacokinetic- pharmacodynamic models Clin Pharmacol Ther 83 909 12 18388873 10.1038/clpt.2008.52 1:CAS:528:DC%2BD1cXlvFOrtb0%3D (Pubitemid 351704927)
15. JB Bulitta NS Ly JC Yang A Forrest WJ Jusko BT Tsuji 2009 Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against pseudomonas aeruginosa Antimicrob Agents Chemother 53 46 56 18852268 10.1128/AAC.00489-08 1:CAS:528:DC%2BD1MXhs1Kksrw%3D
16. CM Ng A Joshi RL Dedrick MR Garovoy RJ Bauer 2005 Pharmacokinetic- pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis Pharm Res 22 1088 100 16028009 10.1007/s11095-005-5642-4 1:CAS:528:DC%2BD2MXmt1yntbw%3D (Pubitemid 41127066)
17. CM Ng A Patnaik M Beeram CC Lin CH Takimoto 2010 Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients Cancer Chemother Pharmacol 10.1007/s00280-010-1393-y
18. CM Ng S Bai CH Takimoto MT Tang AW Tolcher 2009 Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients Cancer Chemother Pharmacol 65 207 10.1007/s00280-009-1023-8 10.1007/s00280-009-1023-8
19. LE Friberg MO Karlsson 2003 Mechanistic models for myelosuppression Investig New Drugs 21 183 94 10.1023/A:1023573429626 1:CAS:528: DC%2BD3sXjtlantrc%3D (Pubitemid 36859318)
20. AC Hooker AJ Ten Tije MA Carducci J Weber E Garrett-Mayer H Gelderblom, et al. 2008 Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements Clin Pharmacol Ther 84 111 8 18183036 10.1038/sj.clpt.6100476 1:CAS:528:DC%2BD1cXnt1KqsLo%3D (Pubitemid 351861492)
21. JB Bulitta P Zhao RD Arnold DR Kessler R Daifuku J Pratt, et al. 2009 Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients Cancer Chemother Pharmacol 63 1049 63 18791718 10.1007/s00280-008-0827-2 1:CAS:528: DC%2BD1MXjslOlurY%3D
22. P Wiczling P Lowe E Pigeolet F Ludicke S Balser W Krzyzanski 2009 Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations Clin Pharmacokinet 48 817 26 19902989 10.2165/11318090-000000000-00000 1:CAS:528:DC%2BC3cXmt1CmtA%3D%3D
23. PP Tanos GK Isbister DG Lalloo CM Kirkpatrick SB Duffull 2008 A model for venom-induced consumptive coagulopathy in snake bite Toxicon 52 769 80 18831981 10.1016/j.toxicon.2008.08.013 1:CAS:528:DC%2BD1cXhtlCktbnJ
24. T Wajima GK Isbister SB Duffull 2009 A comprehensive model for the humoral coagulation network in humans Clin Pharmacol Ther 86 290 8 19516255 10.1038/clpt.2009.87 1:CAS:528:DC%2BD1MXhtVGqu7nF
25. HL Fung PS Tsou JB Bulitta DC Tran NA Page D Soda, et al. 2008 Pharmacokinetics of 1, 4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailability AAPS J 10 56 69 18446506 10.1208/s12248-007-9006-3 1:CAS:528:DC%2BD1cXhtVWrsLrN
26. L Xu JL Eiseman MJ Egorin DZ D'Argenio 2003 Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17- demethoxygeldanamycin and its active metabolite in tumor-bearing mice J Pharmacokinet Pharmacodyn 30 185 219 14571691 10.1023/A:1025542026488 1:CAS:528:DC%2BD3sXmvFamsbc%3D (Pubitemid 37176045)
27. A Marathe MC Peterson DE Mager 2008 Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients J Pharmacol Exp Ther 326 555 62 18460643 10.1124/jpet.108.137703 1:CAS:528: DC%2BD1cXpsVWqs7o%3D